Emerging research underscores the potential of personalised approaches to improve outcomes for women with gestational diabetes, highlighting the need for integrating genetic, microbiome, and patient preferences into tailored treatment strategies.
Gestational diabetes is increasingly being recognised as a major pregnancy complication with consequences that extend well beyond delivery. A 2022 study in PubMed estimated the global standardised prevalence at 14.0% in 2021, with the highest rates in the Middle East and North Africa and South-East Asia. Research also shows that many women face a substantial chance of the condition returning in later pregnancies, while later type 2 diabetes risk remains markedly elevated. Taken together, the figures point to a condition that is common, recurrent and closely linked to long-term metabolic harm.
Against that backdrop, the case for more individualised care is becoming harder to ignore. The review argues that the current approach to gestational diabetes still leans too heavily on standard protocols, even though women differ widely in risk profile, treatment response and personal circumstances. It says shared decision-making can help close that gap by giving patients a greater role in choosing between screening, dietary change, medication and delivery planning, while precision medicine offers a way to tailor care using genetic, metabolic and environmental information.
The practical appeal of shared decision-making is straightforward: it can make care more understandable, more acceptable and easier to follow. The review notes that women often want to take part in choices about their treatment, especially when they are given clear information and several options. It also highlights the barriers that still get in the way, including time pressure, technical language, paternalistic habits in healthcare and lower health literacy. When those barriers are present, patients may feel sidelined, anxious and less likely to trust the care plan.
Precision medicine may help solve some of those problems by moving treatment away from a one-size-fits-all model. The review points to genetic differences such as variants in MTNR1B, which have been linked to fasting glucose levels and risk of gestational diabetes, particularly in women with higher pre-pregnancy body weight. It also examines gut microbiota research, which suggests that pregnancy-related changes in intestinal bacteria may influence glucose control and response to diet. Although these findings are still emerging, they support the idea that better risk stratification could lead to earlier intervention and more targeted treatment.
The authors also carried out a small bibliometric exercise to gauge how often precision medicine is appearing in diabetes research. Using Web of Science Core Collection data searched in February 2026, they found 2,879 hits for precision medicine in diabetes but only 60 for precision medicine in gestational diabetes. The paper says the first publications on diabetes appeared 4 years earlier than those on gestational diabetes and that the strongest concentration of research sits in endocrinology and metabolism. That imbalance, the authors argue, underlines how much room remains for growth in this field.
The broader message is that better outcomes in gestational diabetes are likely to depend on combining scientific tailoring with patient choice. The review concludes that precision medicine and shared decision-making should be developed together, not separately, so that care can reflect both biological risk and personal preference. It also warns that the evidence base is not yet strong enough for widespread adoption without pilot programmes and clinical trials, especially if services are to bring together obstetrics, endocrinology, nutrition and psychology in a workable model of care.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
